Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target

Eitemau Tebyg

• The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
  gan: David, Justin, et al.
  Cyhoeddwyd: (2014)
• Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
  gan: David, Justin M, et al.
  Cyhoeddwyd: (2015)
• Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
  gan: Hamilton, Duane H., et al.
  Cyhoeddwyd: (2014)
• Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of Brachyury and other drivers of the mesenchymal-like phenotype of carcinomas
  gan: Hamilton, Duane H., et al.
  Cyhoeddwyd: (2012)
• The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells
  gan: Fernando, Romaine I., et al.
  Cyhoeddwyd: (2010)